Literature DB >> 28278499

Recurrence and Risk Factors for Relapse in Patients with Non-Small Cell Lung Cancer Treated by Surgery with Curative Intent.

Cristiana Cruz1, Margarida Afonso, Bárbara Oliveiros, Alice Pêgo.   

Abstract

INTRODUCTION: Surgery remains the potentially curative treatment for early-stage non-small cell lung cancer (NSCLC). Despite this, tumor recurrence is the most common cause of treatment failure after surgery.
METHODS: Data were collected retrospectively from clinical files of patients who underwent lung surgery for NSCLC from January 2008 to December 2012 in a University Hospital. Demographic data, tumor characteristics, type of surgery and recurrence were recorded. A comparison of the distribution of variables using adjustment tests was made.
RESULTS: The study included 102 patients, 68.6% were male with a mean age of 63.7 ± 9.3 years old. The majority of tumors had a peripheral location (72.5%) and consisted of adenocarcinomas (61.8%). The most frequently performed surgery was lobectomy. Recurrence was noted in 43.1% of cases. Mean disease-free survival was 57.9 ± 3.8 months. Multifactorial analyses showed that stage IIIA, tumor located in other lobes than the right lower lobe and pleural invasion were independent predictors of recurrence.
CONCLUSION: Our recurrence rate was similar to those in the international literature. As in other studies, we found a positive relation between the lymphatic permeation and pleural invasion and the risk of lung cancer recurrence. We consider that some characteristics of the tumor should be assessed to define alternative modalities of treatment and follow-up in order to predict and rapidly recognize the recurrence.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Non-small cell lung cancer; Recurrence; Risk factor; Surgery

Mesh:

Year:  2017        PMID: 28278499     DOI: 10.1159/000458533

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  6 in total

1.  Postoperative Adverse Events are Associated with Oncologic Recurrence Following Curative-intent Resection for Lung Cancer.

Authors:  Stephen Gowing; Laura Baker; Alexandre Tran; Zach Zhang; Hilalion Ahn; Jelena Ivanovic; Caitlin Anstee; Emma Grigor; Sebastien Gilbert; Donna E Maziak; Farid Shamji; Sudhir Sundaresan; Patrick James Villeneuve; Andrew J E Seely
Journal:  Lung       Date:  2020-10-09       Impact factor: 2.584

2.  Preoperative D-dimer level is an independent prognostic factor for non-small cell lung cancer after surgical resection: a systematic review and meta-analysis.

Authors:  Han-Yu Deng; Xi Zheng; Rui Jiang; Rui-Lan Wang; Jie Zhou; Xiao-Ming Qiu
Journal:  Ann Transl Med       Date:  2019-08

3.  Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma.

Authors:  Qiwen Li; Li Ma; Bo Qiu; Yuzhi Wen; Wenhua Liang; Wanming Hu; Naibin Chen; Tian Zhang; Shuangbing Xu; Lingjuan Chen; Minzhang Guo; Yi Zhao; Songran Liu; Jinyu Guo; Junye Wang; Siyu Wang; Xin Wang; Qingsong Pang; Hao Long; Hui Liu
Journal:  Curr Oncol       Date:  2021-04-07       Impact factor: 3.677

4.  Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis.

Authors:  Florian Eichhorn; Mark Kriegsmann; Laura V Klotz; Katharina Kriegsmann; Thomas Muley; Christiane Zgorzelski; Petros Christopoulos; Hauke Winter; Martin E Eichhorn
Journal:  Cancers (Basel)       Date:  2021-04-23       Impact factor: 6.639

5.  Circ-PITX1 Promotes the Progression of Non-Small Cell Lung Cancer Through Regulating the miR-1248/CCND2 Axis.

Authors:  Qianyu Yue; Yanyan Xu; Xiaoli Deng; Shenglan Wang; Jingman Qiu; Baojiang Qian; Yunhui Zhang
Journal:  Onco Targets Ther       Date:  2021-03-09       Impact factor: 4.147

6.  Surgery and subsequent risk of non-small cell lung cancer recurrence: a meta-analysis of observational studies.

Authors:  Jia Hu; Huikai Miao; Rongzhen Li; Zhesheng Wen
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.